SCHEMBL446711

SCHEMBL446711

CCOC(=O)c1ccc(N2N=C(C)C(=Cc3ccc(O)cc3)C2=O)cc1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KAT8 Q9H7Z6 3/20 0.60
ALDH1A1 P00352 4/20 0.56
MAPT P10636 4/20 0.56
L3MBTL1 Q9Y468 4/20 0.56
TDP1 Q9NUW8 3/20 0.56
POLB P06746 2/20 0.56
MAPK1 P28482 1/20 0.56
HTT P42858 1/20 0.56
RECQL P46063 1/20 0.56
SIRT5 Q9NXA8 3/20 0.55
KMT2A Q03164 8/20 0.54
MEN1 O00255 7/20 0.54
HPGD P15428 2/20 0.53
KDM4E B2RXH2 2/20 0.52
USP2 O75604 1/20 0.52
SAE1 Q9UBE0 1/20 0.52
UBA2 Q9UBT2 1/20 0.52
PTGS2 P35354 1/20 0.52
CA12 O43570 1/20 0.51
CA1 P00915 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL420802 1.00 KAT8 (0.60) KAT8ALDH1A1MAPTL3MBTL1TDP1
SCHEMBL446710 1.00 KAT8 (0.60) KAT8ALDH1A1MAPTL3MBTL1TDP1
SCHEMBL447823 0.86 ERO1A (0.49) KAT8ALDH1A1MAPTL3MBTL1TDP1
SCHEMBL420803 0.86 ERO1A (0.49) KAT8ALDH1A1MAPTL3MBTL1TDP1
SCHEMBL444177 0.85 AMY1A (0.56) KAT8ALDH1A1MAPTL3MBTL1TDP1
SCHEMBL14562410 0.85 KAT8 (0.66) KAT8ALDH1A1MAPTL3MBTL1TDP1
SCHEMBL420572 0.85 AMY1A (0.56) KAT8ALDH1A1MAPTL3MBTL1TDP1
SCHEMBL8078405 0.85 KAT8 (0.81) KAT8ALDH1A1MAPTL3MBTL1TDP1
SCHEMBL443203 0.85 KAT8 (0.81) KAT8ALDH1A1MAPTL3MBTL1TDP1
SCHEMBL420591 0.85 KAT8 (0.81) KAT8ALDH1A1MAPTL3MBTL1TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140335517-A1 DETECTION AND TREATMENT OF SCHIZOPHRENIA RENASCIENCE CO LTD (JP) 2014-11-13 US disclosed
US-8809329-B2 Detection and treatment of schizophrenia TOKYO METROPOLITAN INSTITUTE OF MEDICAL SCIENCE (JP) 2014-08-19 US disclosed
EP-2662453-A2 Detection and treatment of schizophrenia TOKAI UNIVERSITY EDUCATIONAL SYSTEM (JP) 2013-11-13 EP disclosed
US-20120065198-A2 Detection and Treatment of Schizophrenia TOKAI UNIVERSITY EDUCATIONAL SYSTEM (JP) 2012-03-15 US disclosed
US-20110028470-A1 Detection and Treatment of Schizophrenia TOKAI UNIVERSITY EDUCATIONAL SYSTEM (JP) 2011-02-03 US disclosed
EP-2189537-A1 DETECTION AND TREATMENT OF SCHIZOPHRENIA TOKAI UNIVERSITY EDUCATIONAL SYSTEM (JP) 2010-05-26 EP disclosed
US-7645882-B2 Inhibitor of protein modification products formation TOKAI UNIVERSITY EDUCATIONAL SYSTEM (JP) 2010-01-12 US disclosed
US-20070123577-A1 Inhibitor of protein modification products formation TOKAI UNIVERSITY EDUCATIONAL SYSTEM (JP) 2007-05-31 US disclosed
EP-1693369-A1 PROTEIN MODIFIER PRODUCTION INHIBITOR TOKAI UNIVERSITY EDUCATIONAL SYSTEM (JP) 2006-08-23 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070123577-A1 Inhibitor of protein modification products formation SERPINB6, PROC, PLPBP KAT8 2951/4885ALDH1A1 3582/4885MAPT 3796/4885
US-20110028470-A1 Detection and Treatment of Schizophrenia GLO1, CBR1, AOX1 KAT8 2833/4885ALDH1A1 240/4885MAPT 4131/4885
US-20120065198-A2 Detection and Treatment of Schizophrenia GLO1, CBR1, AOX1 KAT8 2833/4885ALDH1A1 240/4885MAPT 4131/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.